TFX - Is it Wise to Hold Teleflex Stock in Your Portfolio Now? | Benzinga
Teleflex (NYSE: TFX) is slated for expansion in the coming quarters, owing to the key growth drivers in the Interventional business. The company's market dominance in Central Venous Catheters and midlines categories is poised to continue, aiming to further increase market share by introducing new products. In addition, the sound solvency position is encouraging. Meanwhile, the impact of macroeconomic challenges on the company's operations remains a concern. Competitive pressures may hinder Teleflex's growth.
In the past year, this Zacks Rank #3 (Hold) stock has declined 11.8% against the 3.4% growth of the industry and the 25.3% rise of the S&P 500 composite.
The global provider of medical technologies has a market capitalization of $9.42 billion. TFX surpassed estimates in each of the trailing four quarters, delivering an average earnings surprise of 6.5%.
Let's delve deeper.
Tailwinds
Strong Surge in the Interventional Segment: The Interventional product category, consisting of a range of applications to diagnose and administer treatment for coronary and peripheral vascular disease, generated 15.4% revenue growth in the first quarter of 2024. This was led by key offerings such as balloon pumps, MANTA, and complex catheters.
Last year, Teleflex expanded the Structural Heart portfolio with the FDA-cleared Wattson Temporary Pacing Guidewire, which is designed specifically for use during transcatheter aortic valve replacement and balloon aortic valvuloplasty procedures.
Image Source: Zacks Investment Research
The company anticipates launching the Ringer Catheter in the back half of 2024, subject to receiving the FDA marketing clearance. Initially, it will be introduced with a PTCA indication with plans for potential label expansion after the ...